New vaccine aims to stop deadly infant diarrhea
NCT ID NCT06663436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new Shigella vaccine in 200 healthy African infants to see if it can prevent severe diarrhea. The vaccine was given in two doses, and researchers measured immune responses and safety. The trial is now complete, and results will show whether this approach is promising.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Shigella vaccine (altSonflex1-2-3)
What this could lead to
If successful, this vaccine could help protect infants in Africa from severe diarrhea caused by Shigella bacteria.
What could go wrong
This is a small, early-phase trial. The vaccine may not produce strong enough immunity or could have side effects. Results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya